Thomas Olin, born in 1958, is Chief Scientific Officer (CSO) & Executive Vice President at Kancera AB, responsible for R&D and IP. Olin has more than 25 years’ experience of R&D and BD in the pharmaceutical industry, in both biotech and big pharma. He has held several senior R&D and BD executive positions, e.g. at Pharmacia and Biovitrum. Olin was responsible for the spin off of iNovacia from Biovitrum in 2006 and was one of the founders of Kancera in 2010. Other assignments include board member of Blasieholmen Investment Group Seed AB (publ). Olin has a Master of Science in biology, chemistry and geosciences and a PhD in physiology from the University of Stockholm. Appointed as CSO in 2023.
Board member since 2010 and former CEO (2010-2023(. Independent in relation to major shareholders.
Back